Insight Molecular Diagnostics Inc. - Common Stock (IMDX)
Healthcare › In Vitro & In Vivo Diagnostic Substances
Price History
Feb 9, 2026 — Mar 29, 2026Investment Snapshot
- Piotroski F-Score 4/9 — moderate financial health
- Loss-making — negative ROE of -89.4%
- Revenue growing at 116% annually
Insight Molecular Diagnostics Inc. - Common Stock (IMDX) is a Healthcare company operating in In Vitro & In Vivo Diagnostic Substances, listed on the NASDAQ , with a market capitalisation of $115 million . Key value metrics: Piotroski F-Score 4 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Insight Molecular Diagnostics Inc. - Common Stock — Fundamental Analysis Summary
On financial health, IMDX shows a moderate Piotroski F-Score of 4/9, and negative return on equity of -89.4% (sector average: -19.8%).
StockPik's composite Value Score for IMDX is 47/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
IMDX reports a high gross margin of 61.5% (sector average: 33.5%) and a negative operating margin of -1,359.4%.
IMDX shows revenue growing at 116% year-over-year, with earnings growing at 17%.